Recent Press Releases

T-DM1 Significantly Improved Progression-Free Survival in Randomized Phase II Trial

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive

GlaxoSmithKline and XenoPort Receive FDA Approval for Horizant™

New treatment for moderate-to-severe primary Restless Legs SyndromeLONDON & RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.--(BUSINESS WIRE)-- GlaxoSmithKline (NYSE: GSK) and XenoPort,

FDA Approves Orphan Drug Vandetanib for Advanced Medullary Thyroid Cancer

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved the orphan drug vandetanib for the treatment of medullary thyroid

Lilly Confirms Date and Conference Call for First-Quarter 2011 Financial Results Announcement

INDIANAPOLIS, April 6, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2011 on Monday, April 18, 2011. Lilly will also conduct a

MonoSol Rx Issued Strategic US Patent Governing the Production of Pharmaceutical Films Containing Specific Drugs and Drug Classe

Patent also covers manufacturing of single and multi-layer films for buccal and sublingual administration utilizing a variety of polymer componentsWARREN, N.J., April 4, 2011 /PRNewswire/ -- MonoSol

HealthSport Signs Letter of Intent to Acquire "Excellent" Rated cGMP Certified Nutraceutical Manufacturing Plant

OXNARD, Calif., March 30, 2011 /PRNewswire/ -- HealthSport, Inc. (OTC Bulletin Board: HSPO), a fully integrated formulator, developer and manufacturer of dissolvable bi-layer oral thin film products

CryoPort (OTCBB: CYRX) Now Fully Integrated into DHL Ordering System for Frozen Shipments

CryoPort Inc. (OTCBB: CYRX), a provider of cold chain frozen shipping systems, in partnership with FedEx (NYSE: FDX) and other companies similar to United Parcel Service Inc. (NYSE: UPS), is now

MIT's Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research

System used for detection of genetic material will help scientists explore molecular basis of diseasesINDIANAPOLIS, April 6, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today

Briscoe Law Firm and Powers Taylor LLP Investigate Inspire Pharmaceuticals, Inc. for Shareholders Concerning Merck Acquisi

DALLAS--(BUSINESS WIRE)-- The Briscoe Law Firm, PLLC, founded by a former state prosecutor and enforcement attorney for the United States Securities and Exchange Commission, and the securities

Harnessing Patients' Good Intentions Can Cut 33% of America's Pharmacy-Related Waste

Express Scripts Report Upends Conventional Thinking on Effective Pharmacy Care ST. LOUIS, April 6, 2011 /PRNewswire via COMTEX/ -- The U.S. can eliminate 33 percent of its annual pharmacy-related

Teva and OncoGenex Present Preclinical Data on the Activity of its Antisense Compound Custirsen (OGX-011/TV-1011) at the A

-- New Data Suggests Novel Strategies for the Treatment of Prostate Cancer -- JERUSALEM, Israel & BOTHELL, Wash. & VANCOUVER, British Columbia--(BUSINESS WIRE)-- Teva Pharmaceutical

Circadian's Partner ImClone Systems Commences First Phase 1 Clinical Trial of VEGFR-3 Antibody IMC-3C5

MELBOURNE, Australia, April 6, 2011 /PRNewswire/ -- Circadian Technologies (ASX.CIR) announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised

Nuron Biotech Acquires Assets Related to HibTITER® Conjugate Vaccine

EXTON, Penn.--(BUSINESS WIRE)-- Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has acquired assets relating to the vaccine HibTITER® (Haemophilus b Conjugate

Roche Joins in Spanish Research Cooperation for Personalized Treatment of Hepatitis B and C

PENZBERG, Germany--(BUSINESS WIRE)-- Roche Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) is cooperating with the Spanish Vall d’Hebron Institute of Research (VHIR), the Networking Biomedical Research

Avandia Lawsuit Settlement News: 'No News is Bad News,' Says Plaintiffs

First Quarter Comes and Goes Without Final Settlement FiguresNEW YORK, April 5, 2011 /PRNewswire/ -- The latest news on the much publicized Avandia Settlement's is: there is no news. After a

In Europe, Emerging Novel Factor Xa Inhibitors Are Set to Displace Use of Low-Molecular-Weight Heparins and Unfractionated

Surveyed Cardiologists Indicate They Would Be Willing to Replace Use of Low-Molecular-Weight Heparins and Unfractionated Heparins with Emerging Agents Such as Apixaban, Otamixaban and Adomiparin,

Retention and Expansion of Bayer HealthCare's East Coast Operations Reaffirms Positive Impact of Christie Administration's Polic

April 4, 2011 - Retention and Expansion of Bayer HealthCare's East Coast Operations Reaffirms Positive Impact of Christie Administration's Policies For Immediate Release: Contact: Fred Snowflack

Bayer Healthcare Selects the State of New Jersey for East Coast Site Consolidation

Wayne, NJ, April 4, 2011 - Bayer HealthCare and the Governor of New Jersey, Chris Christie, are proud to announce that the company has selected New Jersey as the new "home" of Bayer HealthCare's